OXGN 13G

Company

Oncotelic Therapeutics, Inc.

Filed

April 16, 2014

Accession Number

0000905383-14-000002

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →